R&G PharmaStudies Co., Ltd. (301333.SZ)
- Previous Close
44.26 - Open
45.53 - Bid 44.44 x --
- Ask 44.45 x --
- Day's Range
43.52 - 45.30 - 52 Week Range
33.05 - 73.08 - Volume
2,496,202 - Avg. Volume
2,163,768 - Market Cap (intraday)
4.335B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
30.24 - EPS (TTM)
1.47 - Earnings Date --
- Forward Dividend & Yield 0.20 (0.45%)
- Ex-Dividend Date Jul 5, 2024
- 1y Target Est
65.75
R&G PharmaStudies Co., Ltd. provides clinical research outsourcing services for pharmaceutical and medical device companies, and scientific research institutions in China. It offers clinical trial consulting, clinical trial operation, data management and statistical analysis, technical services and solutions, biostatistical quantitative scientific support, and various services related to the clinical trial data monitoring committee, including participating in the committee or relevant statistical analysis for the committee. The company also provides clinical pharmacology services; biological sample testing services to analyze and detect the biological samples collected during the clinical trial, and to determine the concentration of the original drug and/or metabolites; and clinical trial site management services. The company was founded in 2008 and is based in Beijing, China.
www.rg-pharma.comRecent News: 301333.SZ
View MorePerformance Overview: 301333.SZ
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 301333.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 301333.SZ
View MoreValuation Measures
Market Cap
4.29B
Enterprise Value
2.63B
Trailing P/E
29.64
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.74
Price/Book (mrq)
2.30
Enterprise Value/Revenue
3.55
Enterprise Value/EBITDA
16.05
Financial Highlights
Profitability and Income Statement
Profit Margin
18.85%
Return on Assets (ttm)
3.43%
Return on Equity (ttm)
7.90%
Revenue (ttm)
744M
Net Income Avi to Common (ttm)
140.22M
Diluted EPS (ttm)
1.47
Balance Sheet and Cash Flow
Total Cash (mrq)
1.78B
Total Debt/Equity (mrq)
3.91%
Levered Free Cash Flow (ttm)
116.07M